Table 3.
Clinical trials of novel agents in the treatment of r/r cHL under recruiting.
| Agents | Function | Intervention | Phase | NCT number |
|---|---|---|---|---|
| AZD7789 | Anti-PD-1 and anti-TIM-3 antibody | Drug: AZD7789 | Phase 1/2 | NCT05216835 |
| THOR-707 | Non-α-selective IL-2 | Drug: THOR-707 Drug: pembrolizumab |
Phase 2 | NCT05179603 |
| Azacitidine | Cytosine nucleoside analogs | Biological: nivolumab Drug: oral azacitidine |
Phase 1 | NCT05162976 |
| Ipilimumab | Anti-CTLA-4 monoclonal antibody | Drug: brentuximab vedotin Biological: ipilimumab Biological: nivolumab |
Phase 1/2 | NCT01896999 |
| AZD4573 | Cyclin-dependent kinase 9 inhibitor | Drug: AZD4573 | Phase 2 | NCT05140382 |
| Ruxolitinib | JAK1/2 inhibitor | Drug: ruxolitinib Drug: nivolumab |
Phase 1/2 | NCT03681561 |
| Decitabine | 2-Deoxycytidine analogs | Drug: camrelizumab and decitabine | Phase 2/3 | NCT04510610 |
| Chidamide | Histone deacetylase inhibitor | Drug: chidamide Drug: camrelizumab Drug: decitabine |
Phase 2 | NCT04233294 |
| TQB2450 | Anti-PD-1 antibody | Drug: TQB2450 | Phase 2 | NCT03800706 |
| CD30.CAR-EBVST cells | CD30.CAR in EBV-specific T cells | Biological: CD30.CAR-EBVST cells | Phase 1 | NCT04288726 |
| HSP-CAR30 | Anti-CD30 CAR-T cells | Biological: HSP-CAR30 | Phase 1/2 | NCT04288726 |
| AFM13 | Anti-CD30/CD16A monoclonal antibody | Biological: AFM13 Drug: cyclophosphamide Drug: fludarabine Drug: fludarabine phosphate Biological: genetically engineered lymphocyte therapy |
Phase 1 | NCT04074746 |